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ABSTRACT 
Recombinant protein production has been widely 
applied for therapeutic and diagnostic applications, 
namely for polyclonal antibody production. Antibodies 
are usually raised against a specific protein by 
immunisation of animals with the purified protein. The 
Escherichia coli host cell is widely used for the bio-
production of proteins with biomedical interest but 
some of them are still difficult to express properly in 
this host system, resulting in insoluble protein 
aggregates. Gene fusion technology has been employed 
to optimise recombinant protein production in E. coli. 
Fusion partners have also been used to increase protein 
immunogenicity. In this work, the immunopotentiating 
properties of a novel fusion partner (H partner) were 
studied. The H partner was fused to three target 
proteins with diagnostic interest: CP12, a 12 kDa 
surface protein from Cryptosporidium parvum oocysts; 
CWP, a cyst wall protein from Giardia lamblia; and 
ENT, a surface protein from Entamoeba histolytica 
trophozoites. The results obtained here show the H 
partner as a promising tool for immunodiagnostic and 
immunoprophylactic purposes. 
 
INTRODUCTION 
Recombinant protein production became a valuable 
technology for the development of biomedical solutions. 
The host cell Escherichia coli has been widely used for 
the bio-production of proteins. In spite of offering a 
rapid and low cost production of the desired protein, 
many proteins of biomedical interest have proved 
difficult to express properly in this host system, 
resulting in insoluble protein aggregates, known as 
inclusion bodies (Jana and Deb 2005; Terpe 2006). 
When using these recombinant proteins (antigens) for 
polyclonal antibody production, most of them fail to 
elicit an immune response, requiring adjuvants for 
immunisation (Knuth, et al. 2000). Fusion protein 
technology has been applied to optimise antigen 
expression in E. coli and also to improve the polyclonal 
antibody production. Several fusion partners had 
already been used for antigen production and 
immunisation, namely, GST and MBP (Kink, et al. 
1998; Lopez-Monteon, et al. 2004). In spite of the 
antigen production improvements, these fusion partners 
often required adjuvants for immunisation. In addition, 
due to the large size of fusion partners, the produced 
polyclonal antibodies were not antigen-specific, 
reacting against both antigen and fusion partner. A 
novel fusion partner of 1 kDa for antigen 
immunisation, the H partner, is presented in this work. 
The immunpotentiating properties of the H partner 
were studied using three antigens with diagnostic and 
therapeutic potential (CP12, CWP and ENT). The 
immune responses obtained were investigated and a 
diagnostic application of the produced polyclonal 
antibodies was explored.  
 
METHODS 
Recombinant antigen production 
The genes that codify for CP12, CWP and ENT 
antigens were previously cloned into the pQE H 
plasmid and into the pQE 30 plasmid. E. coli M15 
[pREP4] cells were grown at 37 ºC in LB medium 
supplemented with specific antibiotics. When the 
O.D.600nm reached 0.5, cells were induced with 1 mM of 
IPTG for 5 hours at 37 ºC for the expression of 
recombinant fusion proteins. Cells were then harvested 
by centrifugation and the resulting pellets were lysed. 
Supernantant fractions were prepared for 
immunisation. 
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Polyclonal antibody production 
Polyclonal antibodies against the H-fused antigens and 
non fused antigens were produced in CD1 female mice. 
Three groups of mice were injected intraperitoneally at 
2 week intervals with the studied antigens, without 
using adjuvants. Blood collection was carried out 
periodically for five times. The mice sera was treated 
and used for ELISA and immunofluorescence assays 
(IFAs). All animal experiments were conducted 
accordingly to the European Communities Council 
Directive (86/609/EEC). 
 
RESULTS AND DISCUSSION 
The expression of all fusion antigens was analysed by 
SDS-PAGE and all the proteins presented a molecular 
weight identical to the expected, calculated by the 
ProtParam Expasy tool (data not shown). The 
polyclonal antibody productions were analysed and 
compared by ELISA. The CP12 and CWP fusion 
antigens elicited an earlier and higher humoral 
response than the non fused ones (Fig. 1.a and 1.b). 
The polyclonal antibody production against the ENT 
antigen was not evaluated. Nevertheless, an humoral 
response was elicited by the fusion antigen HENT, as it 
can be observed in Fig. 1.c.  
a b  
c  
Figure 1. ELISA results of the produced polyclonal 
antibodies. NC – negative control mice 
group.H”Antigen” – mice group injected with the 
fusion antigens or “Antigen” – with the non-fused ones. 
 
The potential application for diagnosis of the respective 
parasite infections in animals was studied by IFAs 
using the polyclonal antibodies produced against the 
fusion antigens. The anti-HCP12 polyclonal antibodies 
detected the native epithopes on the surface of 
Cryptosporidium parvum oocysts (Fig. 2.a). The anti-
HCWP polyclonal antibodies presented a similar 
detection result, identifying the native epithopes on the 
surface of Giardia lamblia cysts (Fig. 2.b). The anti-
HENT polyclonal antibodies were able to detect the 
native parasite structures exhistent on a commercial 
plate of Entamoeba histolytica trophozoites (Fig. 2.c). 
a  b  c  
Figure 2. Detection of the native parasite structures 
using the produced polyclonal antibodies: a) anti-
HCP12, b) anti-HCWP, c) anti-HENT. 
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